0001005201-20-000012.txt : 20200212
0001005201-20-000012.hdr.sgml : 20200212
20200212184118
ACCESSION NUMBER: 0001005201-20-000012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200212
FILED AS OF DATE: 20200212
DATE AS OF CHANGE: 20200212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HIGGINS ARTHUR J
CENTRAL INDEX KEY: 0001142083
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13111
FILM NUMBER: 20606205
MAIL ADDRESS:
STREET 1: C/O ZIMMER, INC.
STREET 2: P.O. BOX 708
CITY: WARSAW
STATE: IN
ZIP: 46580
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Assertio Therapeutics, Inc
CENTRAL INDEX KEY: 0001005201
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943229046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
BUSINESS PHONE: (224) 419-7106
MAIL ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
FORMER COMPANY:
FORMER CONFORMED NAME: DEPOMED INC
DATE OF NAME CHANGE: 19970408
4
1
wf-form4_158155085976896.xml
FORM 4
X0306
4
2020-02-12
0
0001005201
Assertio Therapeutics, Inc
ASRT
0001142083
HIGGINS ARTHUR J
ASSERTIO THERAPEUTICS, INC.
100 SOUTH SAUNDERS ROAD, SUITE 300
LAKE FOREST
IL
60045
1
1
0
0
Director, President and CEO
Common Stock
2020-02-12
4
M
0
97412
0
A
275747
D
Common Stock
2020-02-12
4
F
0
31008
1.35
D
244739
D
Common Stock
175000
I
By Trust
Common Stock
3000
I
By Child
Restricted Stock Units
2020-02-12
4
M
0
97412
0
D
2022-02-12
Common Stock
97412.0
194825
D
Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022.
The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
/s/ Jennifer Hipelius, attorney in fact
2020-02-12